Lonza launched its new GS Effex cell line for the development of therapeutic antibodies with enhanced potency. The GS Effex cell line was developed to meet pressing market needs originating from the shift towards more sophisticated therapeutic antibodies. Derived from Lonza’s leading GS Xceed cell line, GS Effex fits effectively into Lonza platforms.

Combined with good cell growth and the ability to produce therapeutic antibodies with increased potency, the new cell line is for therapeutic development from discovery stage research through to commercial manufacturing.

According to Lonza, the stable, scalable, and productive cell line produces Fc domains free of fucose, which increases the antibody-dependent cellular cytotoxicity (ADCC) function and therapeutic potency of the final antibody. GS Effex is available under license or as a complete service offering.

Ulrich Osswald, vice president, licensing, Lonza, said, “Lonza is committed to providing our customers with the right tools to develop their novel therapies. Leveraging more than 35 years of protein expression expertise, more than 75 molecules have been manufactured and brought to the clinic using our expression platforms. The new GS Effexcell line represents an enhanced solution especially relevant for the oncology field since improved ADCC represents a vital enhancement of the therapeutic success of an antibody product.”

Lonza’s GS Gene Expression System includes Lonza’s host cell lines, GS Xceed and GS Effex, GS piggyBac transposon technology, GS Discovery transient expression system, vectors, optimized processes, and expertise.